The Fort Worth Press - Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

USD -
AED 3.672498
AFN 65.000023
ALL 82.324126
AMD 360.954502
ANG 1.790403
AOA 917.999843
ARS 1546.245702
AUD 1.480845
AWG 1.8
AZN 1.69704
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.6704
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.427285
CDF 2315.000247
CHF 0.838445
CLF 0.025355
CLP 997.910145
CNY 6.67175
CNH 6.670535
COP 3319.96
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.146958
DJF 178.554905
DKK 6.781825
DOP 60.996961
DZD 137.215041
EGP 53.666204
ERN 15
ETB 164.576405
EUR 0.90722
FJD 2.27435
FKP 0.756889
GBP 0.756925
GEL 2.589897
GGP 0.756889
GHS 11.756648
GIP 0.756889
GMD 73.999788
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.845525
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.085501
IDR 18267
ILS 3.21895
IMP 0.756889
INR 94.05615
IQD 1520.102326
IRR 1913737.493849
ISK 123.920313
JEP 0.756889
JMD 158.434973
JOD 0.709006
JPY 159.380496
KES 130.049912
KGS 87.435502
KHR 4119.418691
KMF 446.999884
KPW 900.00035
KRW 1334.339988
KWD 0.31147
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.830219
MMK 2100.274506
MNT 3605.662913
MOP 8.103614
MRU 40.552456
MUR 47.810103
MVR 15.402503
MWK 1738.739965
MXN 18.58995
MYR 4.092495
MZN 63.843843
NAD 16.951268
NGN 1343.350271
NIO 36.903315
NOK 9.574275
NPR 151.114437
NZD 1.81089
OMR 0.385095
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.933502
PKR 277.274459
PLN 3.997335
PYG 6223.068898
QAR 3.655265
RON 4.851503
RSD 106.693821
RUB 82.54671
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.875029
SDG 601.501052
SEK 10.075065
SGD 1.288355
SHP 0.752984
SLE 23.049758
SLL 20969.503664
SOS 573.051087
SRD 37.490172
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.869465
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392598
TTD 6.806306
TWD 32.987012
TZS 2651.411999
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25747.5
VUV 120.320092
WST 2.810586
XAF 595.097238
XAG 0.021048
XAU 0.000259672138
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.097238
XPF 108.186074
YER 236.549835
ZAR 16.97378
ZMK 9001.198917
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.086045
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete

Test results support the next development step with Phase 1clinical trial expected to commence in April

Provides Summary of Expected 2025 Milestones

Text size:

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, announced today that Glatt Air Techniques, Inc., part of Glatt Group, a vertically integrated pharmaceutical services company with FDA- and EU-approved sites operating under cGMP conditions, has undertaken FDA-required testing of the Company's high-dose sublingual aspirin product. Based on the feasibility study, Aspire has begun preparations and expects its next phase of clinical trial to commence in April.

Aspire's lead product candidate, high-dose sublingual aspirin, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin designed to address cardiology emergencies and pain management. Aspire believes the benefits of "rapid absorption" aspirin include the potential to quickly stop heart attack and stroke; allow high dose absorption for pain management including fast headache relief, post-surgery, cancer pain management, and general pain relief.

The Company's formulation was deemed feasible for further development based on the following testing reports provided by Glatt:

  • Validated Aspire's analytical methods for manufacturing the product under cGMP standards.

  • Demonstrated that the aspirin and other ingredients purchased for the testing batch of our high-dose aspirin product meets cGMP and FDA standards for purity.

  • Proved through a compatibility study that the active ingredient (aspirin) is compatible with the incipient ingredients without issues that could occur in the packaged final product.

  • Established baselines for our stability testing to assure appropriate shelf-life.

  • Verified the two flavors our high-dose aspirin will use (orange and lemon lime) are chemically compatible with the product's other ingredients.

Based on the growing volume of pre-clinical data reported by the Company, management believes clear proof-of-concept has been established for its underlying delivery technology.

"Today's announcement represents a significant milestone for Aspire, and we believe the speed and level of absorption due to our new mechanism of action into the blood stream is significant and represents a new disruptive drug delivery technology," commented Kraig Higginson, Chief Executive Officer of Aspire. "The feasibility data of our high-dose sublingual aspirin announced today builds on the strong data reported to date, as we work to finalize the path forward for next round of clinical testing in April 2025. We look forward to advancing the study to bring an innovative treatment option to patients and further demonstrate that our novel drug delivery technology will support the lifecycle of Aspire's drug and nutraceutical development pipeline."

High-dose, sublingual aspirin - Aspire's Expected Lead Product

Aspire's lead product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin. Aspire believes the benefits of "rapid absorption" aspirin include the potential to quickly stop heart attack and stroke; allow high dose absorption for pain management including fast headache relief, post-surgery, cancer pain management, and general pain relief. Aspire is in the process of seeking approval from the U.S. Food and Drug Administration ("FDA") for its aspirin product. Aspire can reference the well-known and fully established safety and efficacy data of the original innovator drug (aspirin) which can accelerate the approval process and reduce associated costs.

Summary of 2025 Expected Milestones

Looking forward, the Company expects to achieve a number of significant milestones in fiscal 2025. These include:

Aspirin Products

  • Initial trial and report high level results

  • Progress meeting with the FDA in the early second quarter of 2025 in conjunction with application

  • Commence final clinical trial to evaluate the pharmacodynamic effect of a single dose of our aspirin product on platelet inhibition compared to that of standard oral aspirin in Q2 2025.

  • Request rapid approval for the high dose aspirin product from the FDA.

  • Clinical trials in Fall 2025 of our low-dose sublingually administered aspirin for preventative care.

  • High dose sublingually administered aspirin for pain relief (rheumatological and other pain). Building on previous clinical trial as set forth above, we anticipate seeking FDA approval, in the latter part of 2025.

Non-aspirin Prescription Drug Products

  • Testosterone formulation for sublingually administered testosterone. Aspire will conduct a Phase 1 clinical test in the third quarter of 2025 for pharmokinetical validation of product properties to establish criteria for an NDA with the FDA. Aspire anticipates, based on these results, to request a pre-IND meeting with the FDA in the fourth quarter of 2025, followed by Phase 2 clinical testing.

  • Semaglutide formulation for a sublingual semaglutide product is nearly complete; FDA approval process to start in late 2025.

  • Early studies of migraine rapid relief product to be delivered via Aspire's rapid drug delivery technology in early Q3 2025.

  • Erectile dysfunction (sildenafil/tadalafil) formulation development in Q4 2025.

Non-prescription Products

  • Pre-workout product using our sublingual delivery method is expected to launch in Q2 2025.

  • Melatonin product for a sublingually administered, rapid-delivery melatonin sleep-aid product expected to launch in Q3 2025.

  • Vitamin development formulation for sublingually administered vitamins D, E and K 2H 2025.

About Aspire Biopharma, Inc.

Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology for rapid product delivery which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma, Inc.



View the original press release on ACCESS Newswire

A.Williams--TFWP